Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothiocyanate SCHEMBL28018733 | 0.85 | — | — | |
| Isothiocyanate SCHEMBL21496008 | 0.85 | — | — | |
| Adamantane SCHEMBL1931599 | 0.75 | CYP2C9 (0.32) | CYP2C9 | |
| Adamantane SCHEMBL932765 | 0.75 | CYP2C9 (0.32) | CYP2C9 | |
| Isothiocyanate SCHEMBL331482 | 0.71 | — | — | |
| Adamantane SCHEMBL1527414 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| Isothiocyanate SCHEMBL4002 | 0.71 | — | — | |
| Isothiocyanate SCHEMBL8940171 | 0.71 | ALDH1A1 (0.43) | — | |
| Adamantane SCHEMBL29707714 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| Adamantane SCHEMBL9016497 | 0.71 | CYP2C9 (0.46) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040266-A1 | HYBRID SUPRAMOLECULAR BIOMATERIAL FOR BIOPRINTING AND CELL CULTURE | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2025-02-27 | — | — | WO | claimed |
| CN-112844472-B | Preparation method and application of chiral imidazole urea catalyst | 深圳市宝安区新材料研究院 | 2023-05-23 | — | — | CN | claimed |
| WO-2025040266-A1 | HYBRID SUPRAMOLECULAR BIOMATERIAL FOR BIOPRINTING AND CELL CULTURE | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2025-02-27 | — | — | WO | disclosed |
| CN-112844472-B | Preparation method and application of chiral imidazole urea catalyst | 深圳市宝安区新材料研究院 | 2023-05-23 | — | — | CN | disclosed |
| CN-109963886-B | Phosphoguanidine group IV metal olefin polymerization catalyst | 陶氏环球技术有限责任公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-112844472-A | Preparation method and application of chiral imidazole urea catalyst | 深圳飞扬兴业科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-111978312-A | 5-aryl-1, 3, 4-thiadiazole/1, 3, 4-oxadiazole-2-amine compound and preparation method and application thereof | 黄淮学院 | 2020-11-24 | — | — | CN | disclosed |
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2142522-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121558-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
| US-20010034333-A1 | Cyclodextrin polymer compositions for use as drug carriers | KOSAK KENNETH M (US) | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034333-A1 | Cyclodextrin polymer compositions for use as drug carriers | ABCB1, ABCG2, CTTN | CYP2C9 67/4885 |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | CYP2C9 1683/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP2C9 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.